TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Insulin stimulated muscle glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cough count agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral oximetry values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative pathological results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jumping distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability (severity and number of adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Sleep Latency N1
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Initiation of Renal Replacement Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Duration of Renal Replacement Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage reduction in premature ventricular contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in Muscle Dysmorphia Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Skin Sensitivity Scores - Redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Skin Sensitivity Scores - Sensitivity to Light
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Skin Sensitivity Scores - Tightness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Skin Sensitivity Scores - Itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Skin Sensitivity Scores - Burning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving Prostate Specific Antigen (PSA) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of sexual violence problem
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of asymptomatic malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Burden of EBV
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Abundance of Skin Gammaproteobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of liver cirrhosis related outpatient contacts
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of liver cirrhosis related radiographic imaging
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of liver cirrhosis related esophagogastroscopies
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of liver cirrhosis related elastographies
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Immediately stone-free rate (SFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative proportion of people with treatment failure
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Time in Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Time in Euglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Time in Hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Smoking abstinence at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of cancer or non-cancer using Harbinger Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Performance for specific cancer types using Harbinger Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identify the correct tumor type by Harbinger Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stent Primary Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from Baseline Six Minute Walk Test (6MWT) with oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Transthoracic Echocardiogram in 3 Dimensions (3-D TTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline Pulmonary Function Test (PFT) with bronchodilation if abnormal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of RP-6306
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 Dose (RP2D) of RP-6306
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of RP-6306
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants who Complete Therapy without Grade III-IV Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with pain >5 on a 0-10 point scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treatment-Emergent Pre-Specified Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to clinical resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of participants with HBsAg loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in correct responses in Confrontation Naming
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in correct responses in Context Generalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State and Trait Anxiety Inventory scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IBD-QOL scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: The Pittsburgh Sleep Quality Index scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Disease Activity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of intervention as measured by the number of participants accrued
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to the intervention as measured by the proportion of dyads successfully completing the four intervention components
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptability of intervention as measured by 8-item Client Satisfaction Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prorated AUC for the global BFI score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Site of lesion determination in ANSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy of 3D-MRE features for portal hypertension assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular pressure decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Reduction of bed-days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rate of sustained alcohol relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Bristol stool scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Students' achievement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants with premature delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mental status and cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: AKI progression at day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of Adverse Events in 28 days following use of ActivSight™
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of reaction of the injection sites
Endpoint domain: Adverse events/effects
Primary endpoint: Adult participant attendance in program as assessed by total number of program sessions attended, core
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Satisfaction with Family Diabetes Prevention Program as assessed by study team designed questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cost of program delivery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Injection related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection related satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive and Negative Symptoms of Schizophrenia (PANSS) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite event
Endpoint domain: Mortality/survival
Primary endpoint: Fugl-Meyer Assessment-UE (FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of high-intensity oral rivaroxaban vs high-intensity warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of TAA and/or aAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number and type of dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: qEEG features changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding Behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: clinical Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: genetic Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biological and/or imaging Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in jump height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sprinting speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants who attended a well woman visit
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Proportion of participants who scheduled a well woman visit
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Proportion of participants who scheduled a well woman visit and did not attend (and did not Cancel and/or Reschedule)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Immune response superiority of SCB-2023 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reactogenicity of SCB-2023 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of SCB-2023 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Cohort Pregnancy Ratio
Endpoint domain: Mortality/survival
Primary endpoint: Cohort Term Live Birth Ratio
Endpoint domain: Mortality/survival
Primary endpoint: Cohort Infant Mortality Ratio
Endpoint domain: Mortality/survival
Primary endpoint: Pulmonary ventilation perfusion (V/Q) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of CHW contacts
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in the Menopause-specific Quality of Life (MENQOL) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in the Menopause Rating Scale (MRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Ofatumumab-treated Patients with an Immune Response to COVID-19 Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bladder preservation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to immunotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: cumulative composite event rate of the main adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: cumulative composite event rate of all-cause death and worsening heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Attitude toward people living with dementia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relative power alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: High frequency heart rate variability (HF-HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: The Body Perception Questionnaire Body Awareness Very Short Form (BPQ-VSF)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in patient proptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum perfusion intensity (Normal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum perfusion intensity (ROI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MR Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Desire to Exercise
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Exercise Adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise Training Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants According to Clinical Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal blood flow density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of methotrexate clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total tramadol consumption in 24 hours
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Salivary levels of TAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Salivary levels of FRAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Salivary levels of leptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Salivary levels of adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Trends in physiological vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutri-Score value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaphragm Thickening Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diffusivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regional myelination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline pain at 10 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of pain at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calgary Depression Scale in Schizophrenia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Buss-perry Aggression Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: accuracy of Electroencephalography signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with fibrosis regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: HBV DNA undetectable rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intradialytic hemodynamic stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intradialytic morbid events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in concentration of artesunate in blood plasma samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in concentration of dihydroartemisinin in blood plasma samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total volume of new heterotopic ossification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serial blood reported
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mortality or AKI progression
Endpoint domain: Mortality/survival
Primary endpoint: Hemodialysis Comfort Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of major complication
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of mortality
Endpoint domain: Mortality/survival
Primary endpoint: Past 30-day alcohol use frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Past 30-day cannabis use frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Past 30-day nicotine use frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical Rating Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline on the 16-item Decisional Conflict Scale (DCS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline on the 4-item SURE screening test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline on the Decision Coach Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of success at first puncture attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to cannulate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diagnostic performance of tissue protein signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of cancer risk in new lung nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative analgesic requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Value of vessel diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Value of volume of blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Value of peak systolic velocity ratio (PSVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Re intervention of fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pulmonary vascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Drain site cellulitis
Endpoint domain: Adverse events/effects
Primary endpoint: Incisional cellulitis
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Impairment Measure post-intervention: Upper Extremity Fugl Meyer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EEG spectral power in Beta band post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in amygdala activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Shoulder Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adverse events after single injection of MDK-703
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of AI models
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activity at the emotion recognition task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain activity at resting state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: White matter integrity in the cerebellum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HACOR score for prediction of failure of NIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROX index for prediction of failure of NIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaphragmatic thickness assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaphragmatic dysfunction assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of EGFR-TKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cases in which the procedure was successful
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of cases in which a biventricular repair was achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes